Toll-like receptor 7 (TLR7) an innate immune sensor for microbial RNA, erroneously responds to selfderived RNA. To avoid autoimmune responses, TLR7 is suggested to be silenced until the N-terminal half of the TLR7 ectodomain (TLR7N) is cleaved off. Resultant truncated TLR7 (TLR7C) is thought to signal microbial RNA. We here show that TLR7N remains associated with TLR7C through a disulfide bond. By N-terminal amino acid sequencing, TLR7C was found to start at 461E or 462A. The newly established monoclonal anti-TLR7N showed that endogenous TLR7 in bone marrow-derived dendritic cells was almost all cleaved and cleaved TLR7N remained in endolysosomes. TLR7N in endolysosomes was linked with TLR7C by a disulfide bond. In contrast, TLR9 did not have a disulfide bond between TLR9N and TLR9C fragments. Among the cysteines unique to the ectodomain of TLR7 but not TLR9 (Cys98, Cys445, Cys475 and Cys722), Cys98 in TLR7N and Cys475 in TLR7C were required for an intramolecular disulfide bond. These cysteines were also needed for proteolytic cleavage of and RNA sensing by TLR7, but not for TLR7 trafficking from endoplasmic reticulum to endosomes. No response was seen in TLR7 mutants lacking the proteolytic cleavage site or TLR7C alone. These results demonstrate requirement for proteolytic cleavage and TLR7N in TLR7 responses and indicate RNA sensing by TLR7N + TLR7C.
Introduction
Toll-like receptors (TLRs) sense a variety of microbial products. Cell surface TLRs including TLR4/MD-2, TLR1/TLR2 and TLR6/TLR2 recognize microbial membrane lipids, whereas TLR3, TLR7, TLR8 and TLR9 reside in intracellular organelles and recognize microbial nucleic acids (1) (2) (3) . TLR7, an innate immune sensor for microbial RNA (4), has been implicated in autoimmune diseases like psoriasis (5) and systemic lupus erythematosus (SLE) (6) (7) (8) . Over-expression of TLR7 in the Yaa or transgenic mice predisposes to lupus nephritis (9, 10) , whereas the lack of the TLR7 gene ameliorates disease progression in lupus-prone mice (6) . Self-pathogen discrimination by TLR7 is error-prone and therefore TLR7 responses need to be tightly controlled. Three mechanisms are proposed to limit TLR7 responses.
Sequestration of self-RNA from endolysosomes, a site for RNA sensing by TLR7, is a mechanism avoiding TLR7 response to self-RNA. Whereas extracellular self-RNA is rapidly degraded by RNase, microbial RNA is protected by bacterial cell walls or viral particles, and transported to endolysosomes (11) . Aberrant transportation of self-RNA to endolysosomes was shown to exacerbate autoimmunity (5, 8, 12) . In autoimmune diseases like SLE, self-RNA is complexed with autoantibodies against the nucleic acid or nucleoproteins, delivered into endosomal compartments via FcR-or BCR-mediated endocytosis, leading to activation of conventional dendritic cells (cDCs) and production of type I interferon (IFN-I) (13) .
TLR7 transportation is a second mechanism restricting TLR7 responses. TLR7 is believed to reside in the endoplasmic reticulum (ER) in the steady state and is transported to endolysosomes upon activation. The TLR7/TLR9 trafficking is controlled by Unc93B1, a multitransmembrane ER-resident protein. Unc93B1 has been shown to bind to TLR7 and transport TLR7 from ER to endolysosomes (14, 15) . Unc93B1 is indispensable for TLR7 responses. Moreover, Unc93B1 has a role in negatively regulating TLR7 responses. TLR9 antagonizes TLR7 by competing for Unc93B1 association (16) (17) (18) . Unc93B1 mutation disrupting TLR9 antagonism causes systemic lethal inflammation due to homeostatic TLR7 activation (16) .
Proteolytic cleavage of the ectodomain of TLR7 in the endolysosomes is a third mechanism restricting TLR7 responses. The ectodomain of TLR7 is intact in ER but cleaved in the endolysosomes by proteases such as cathepsins (19) . Proteolytic cleavage of the ectodomain has been shown to be required for TLR7 signaling (19) .
These mechanisms were proposed on the basis of overexpressed TLR7 in cell lines. Little is known about processing of endogenous TLR7 in primary immune cells such as macrophages and cDCs. We here established anti-mouse TLR7 and examined processing and subcellular distribution of TLR7 in primary immune cells.
Methods

Generation of anti-mouse TLR7 monoclonal antibodies
To establish an anti-mouse TLR7 monoclonal antibody (mAb), BALB/c mice were immunized several times with Ba/ F3 cells expressing flag-6xHis-conjugated mouse TLR7 (Ba/ F3-mTLR7fH). Five days after the final immunization, splenic cells were fused with SP2/O myeloma cells. A hybridoma producing an anti-TLR7 mAb was selected by flow cytometry staining of Ba/F3 cells expressing mTLR7fH. This mAb, named A94B10 (mouse IgG1/κ), was used in this study.
Mice, reagents and cells
C57BL/6 mice were purchased from Japan SLC, Inc. (Shizuoka, Japan). TLR7 −/− mice on C57BL/6 background were kindly provided by Prof. S. Akira (Osaka University, Japan). All animal experiments were conducted with the approval of the Animal Research Committee of the Institute of Medical Science, The University of Tokyo.
Biotinylated anti-Flag antibody (clone M2) and anti-Flag M2 agarose affinity gel were purchased from Sigma-Aldrich. Rabbit Green Fluorescent Protein (GFP) polyclonal antibody (pAb) and mAb (FM264) were purchased from Invitrogen and MBL, respectively. The pAbs to the N-terminal fragment of TLR7 (TLR7N) or the C-terminal fragment (TLR7C) were established by immunizing rabbits with the glutathione S-transferase fusion protein containing mouse TLR7 ectodomain (aa 47-176 for TLR7N and 583-701 for TLR7C). Paraformaldehyde (PFA) and Blocking One for immunofluorescence staining were purchased from Thermo Scientific and Nacalai tesque, respectively.
RNA9.2s-DR (5′-UGUCCUUCAAUGUCCUUCAA-3′) (20) was synthesized by Hokkaido System Science. Pam 3 CSK 4 was purchased from EMC Microcollections. Loxoribine (7-allyl-7,8-dihydro-8-oxoguanosine) and gardiquimod were purchased from InvivoGen.
RAW264 cells with the shRNA targeting PRAT4A (shPRAT4A) were generated in our laboratory as previously described (21) . RAW264 cells with or without shPRAT4A were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin-glutamine (Gibco) and 50 μM 2-ME. Ba/F3 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% FBS, penicillin-streptomycin-glutamine and 50 μM 2-mercaptoethanol(2-ME). IL-3 was added into culture medium for Ba/F3 cells.
Bone marrow-derived DCs (BM-cDCs) were prepared as previously described (16, 21) . In brief, BM cells were plated at 10 6 cells per 10 ml with 10% FCS-RPMI 1640 supplemented with 10 ng ml −1 of recombinant mouse granulocyte macrophage colony-stimulating factor (PeproTech, Rocky Hill, NJ, USA) in 10-cm cell culture dishes. Half of the volume of medium was changed every other day. At day 7, BM-cDCs were harvested and used for immunoprecipitation and confocal microscopy.
Plasmid constructs
The epitope tags (Flag-6xHis, GFP) were attached to the C-termini of mouse TLR3, TLR7, TLR8 and TLR9 as previously described (18) . TLR7 fusion protein (Fig. 1C) was generated by cloning the TLR7 ectodomain into p Display vectors (Invitrogen). The fusion proteins consist of the murine Igkchain leader sequence, TLR7 ectodomain and the plateletderived growth factor receptor (PDGFR) transmembrane domain. The DNA fragment encoding the TLR7 fusion protein was finally tagged with the Flag-6xHis at the C-terminus and cloned into the pMX vector by In-Fusion HD Cloning Kits (TaKaRa). TLR7 mutants replacing cysteines with serine were generated by the PrimeSTAR Mutagenesis Basal Kit (TaKaRa) and cloned into pMX vectors. Ba/F3 cells expressing NF-κB-GFP (BaκB) were previously described (18) .
Retroviral transduction
pMX and pMXpuro vectors were transfected into Plat-E packaging cells with FuGene6 (Roche Applied Science). After 2 days of incubation, supernatants were obtained as virus suspensions. Ba/F3 and BaκB cells were infected by virus suspensions mixed with DOTAP (Roche Applied Science).
TLR7 cleavage site analysis
TLR7-GFP was stably expressed in the RAW264 cell line. Next, 1 × 10 10 transfectants were collected and lysed in the buffer [150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 0.5% TritonX-100, 10 μg ml −1 ml −1 aprotinin, 10 μg ml −1 leupeptin, 1 mM phenylmethylsulphonylfluoride]. Anti-GFP agarose beads were added to the lysate and incubated overnight at 4°C. Beads were collected and washed four times by washing buffer [150 mM NaCl, 30 mM Tris-HCl (pH 7.4), 0.1% TritonX-100], and bound protein was eluted in a buffer [150 mM NaCl, 30 mM Glycine-HCl (pH 2.5), 0.1% TritonX-100]. Eluted sample was dialyzed in buffer (10 mM NaCl, 0.1% TritonX-100) and concentrated by frozen dehydration. Concentrated sample was dissolved in the sample buffer [2% SDS, 10% glycerol, 62.5 mM Tris-HCl (pH 6.8), 0.025% bromo phenol blue, 5% 2-ME] and subjected to SDS-PAGE. Separated protein was transferred to polyvinylidene difluoride (PVDF) membranes. Transferred protein was visualized by Coomassie 414 TLR7-unique cysteines brilliant blue and the membrane containing TLR7C was cut out. The membrane was subjected to N-terminal amino acid sequencing by Edman degradation (APRO Science Co., Ltd).
Immunoprecipitation
Cells were collected and washed two times with 1× PBS. Washed cells were lysed with 1% digitonin lysis buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10% glycerol, 1 mM dithiothreitol (DTT), 1× complete EDTA-free cocktail (Roche Applied Science)]. After incubation for 30 min on ice, lysates were centrifuged and debris was removed. The cell lysates were rotated for 2 h at 4°C with beads coupled with anti-Flag or anti-TLR7N mAb. The beads were then washed with 0.1% digitonin washing buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10% glycerol, 1 mM DTT] three times. Immunoprecipitates were subjected to SDS-PAGE after boiling in reduced sample buffer [125 mM Tris-HCl (pH 6.8), 20% glycerol, 4% SDS, 10% 2-ME, 0.005% bromophenol blue] or non-reduced sample buffer [125 mM Tris-HCl (pH 6.8), 20% glycerol, 4% SDS, 0.005% bromophenol blue]. After electrophoresis, samples were transferred to PVDF membranes and subjected to immunoblotting.
Luciferase assay
HEK293 cells (1 × 10
6 cells per well) were transiently transfected in 6-well plates using Lipofectamine 2000 reagent (Invitrogen) with pMX TLR7 or pMX cysteine mutant vector (5 μg), together with a luciferase-linked NF-κB reporter gene, pELAM1-Luc (25 ng) (22) . Twenty-four hours after transfection, cells were harvested and seeded into 96-well plates (5 × 10 4 per well). After 12 h, cells were stimulated with medium alone, Loxoribine, gardiquimod or human TNFα for 6 h. The cells were lysed using lysis buffer (Promega) and luciferase activity was measured by luminometer. Data are expressed as mean values with standard deviation (SD) from triplicates.
Immunofluoresence staining and confocal microscopy
BM-cDCs were incubated on a poly-l-lysine-coated 15-mm micro cover glass overnight to allow them to adhere. Then cells were fixed with 4% PFA in 1× PBS. After fixation, cells were washed with 1× PBS two times and treated with 0.1% TritonX-100 in blocking buffer (0.5× PBS with 2.5% BSA and 0.01% NaN 3 , 50% Blocking One) for 30 min at room temperature for intracellular staining. Treated cells were washed with 1× PBS two times and stained with 1 μg ml −1 purified mouse anti-mouse TLR7 mAb and 0.5 μg ml −1 rabbit anti-mouse calnexin (ab22595) in blocking buffer for 90 min at 37°C. After incubation, cells were washed three times and stained with 1 μg ml −1 anti-mouse Alexa488 (Invitrogen) and 1 μg ml −1 antirabbit Alexa568 (Invitrogen), 4′,6-diamidino-2-phenylindole for 90 min at 37°C. Stained BM-cDCs were washed with 1× PBS three times and mounted with PermaFluor Aqueous Mounting Medium (Thermo Scientific). Confocal microscopy was performed on a confocal microscope (LSM710; Carl Zeiss, Inc.).
Ba/F3 cells were treated with a buffer containing 0.1% saponin (Wako), followed by staining with 0.5 μg ml −1 biotinylated anti-mouse TLR7 mAb and 0.5 μg ml −1 rabbit antimouse calnexin in 0.1% saponin buffer at 4°C for 40 min. 
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After the first antibody staining, cells were washed with 0.1% saponin buffer two times and were stained with 0.1 μg ml −1 phycoerythrin (PE)-streptavidin (BioLegend) and 0.5 μg ml −1 anti-rabbit Alexa647 (Invitrogen). Stained Ba/F3 cells were washed three times with 0.1% saponin buffer and examined on a confocal microscope (LSM710; Carl Zeiss, Inc.).
Statistical analysis
Data from triplicate samples were used for statistical analysis. Statistical significance was calculated by the Student's t-test.
Results
Establishment of anti-TLR7 and determination of the TLR7 cleavage site
To study endogenous TLR7, we established an anti-TLR7 mAb. The specificity of the mAb was verified by membranepermeabilized staining and immunoprecipitation of Ba/F3 cells expressing TLR3, TLR7, TLR8 or TLR9 ( Fig. 2A and B) . TLR7 was specifically stained and immunoprecipitated by the newly established mAb. Considering a critical role for proteolytic cleavage in TLR7-mediated responses (19) , it was important to determine whether the TLR7 mAb reacts with TLR7N or TLR7C of the TLR7 ectodomain. For this purpose, we first determined the cleavage site of the TLR7 ectodomain. RAW264 cells expressing TLR7-GFP were established. TLR7-GFP was immunoprecipitated by anti-GFP and compared with TLR7-GFP expressed in PRAT4A-silenced RAW264 cells. PRAT4A silencing efficiency was confirmed by immunoprobing of the cell lysates with anti-PRAT4A (Fig. 1A , right panel, compare lanes 1 and 3). PRAT4A is a TLR-specific chaperone and TLR9 remains in ER in the absence of PRAT4A (21) . Two TLR7 signals were detected in control RAW264 cells, whereas the lower TLR7 was missing in PRAT4A-silenced RAW264 cells (Fig. 1A, left panel) . Considering that TLR7 and TLR9 are not cleaved in ER (19) , the remaining and missing TLR7 in PRAT4A-silenced cells were identified as TLR7F and TLR7C, respectively. Based on these results, TLR7 was purified by anti-GFP, and the N-terminal amino acid sequence of TLR7C was determined (see Methods). TLR7C was found to start at 461E or 462A, suggesting that TLR7 was cleaved between 460L and 461E or between 461E and 462A (Fig. 1B) . These sites lie in the region between the 14th and 15th leucine-rich repeat (LRR), which corresponds to the region predicted to be cleaved in TLR9 (23) (24) (25) . According to the cleavage sites, TLR7 ectodomains ranging from 27 to 457, 461 to 837 or 27 to 837 were expressed in Ba/F3 cells as a chimeric protein consisting of a signal peptide, each TLR7 ectodomain, a transmembrane domain and the flag epitope (see Methods). These cells were subjected to membrane-permeabilized staining. TLR7 mAb reacted with TLR7N, but not with TLR7C (Fig. 1C) .
Intramolecular disulfide bond between TLR7N and TLR7C
The subcellular distribution of TLR7 affects TLR7 responses, but that of endogenous TLR7 has never been studied because of the lack of TLR7 mAb. BM-cDCs were next stained with the TLR7N mAb to detect endogenous TLR7. Anti-calnexin was used for staining the ER. The specificity of anti-TLR7 was confirmed by the lack of positive staining in TLR7 −/− BM-cDCs (Fig. 3A, bottom) . Contrary to our expectation that TLR7 resides in ER in the steady state, TLR7 was largely detected outside ER (Fig. 3A) . Consistent with this, biochemical analyses showed that most TLR7 was cleaved and full-length TLR7 (TLR7F) was hardly detected in BM-cDCs (Fig. 3B, lane 2) . It was possible that our mAb was able to precipitate only TLR7N. This was, however, not the case. The TLR7N mAb was able to precipitate over-expressed TLR7F from Ba/F3 cells (Fig. 3B, lane 4) and endogenous TLR7F from a macrophage cell line RAW264 (Fig. 3C, lane 2) . These results demonstrate that TLR7 in the steady-state BM-cDCs is mostly processed and localized outside ER. Cleaved TLR7N remained in endolysosomes instead of being secreted or degraded, raising the question of whether TLR7N is anchored by another molecule. TLR7C is one of the possible molecules associated with TLR7N. In this regard, we found that TLR7N and TLR7C from RAW264 cells were detected under reduced conditions but not under non-reduced conditions (Fig. 3C, compare lanes 2 and 4) , demonstrating a disulfide bond between TLR7N and TLR7C. TLR9 was next immunoprecipitated from RAW264 cells. In contrast to TLR7, endogenous TLR9C was detected under non-reduced conditions (Fig. 3D, lane 2) , demonstrating that TLR9 does not have a disulfide bond between TLR9N and TLR9C.
TLR7-unique cysteines required for TLR7 responses
To address a role for a disulfide bond in TLR7 responses, roles for cysteines in TLR7 responses had to be studied. Given that a disulfide bond was not found in TLR9, the amino acid sequences of TLR7 and TLR9 were compared to identify TLR7-unique cysteines in the TLR7 ectodomain. Four cysteines, C98, C445, C475 and C722 were shared by mouse and human 
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TLR7, but not by mouse/human TLR9 or TLR8 (Fig. 4) . C98 and C445 lie in TLR7N, whereas C475 and C722 are in TLR7C. TLR7 mutants replacing each cysteine with serine were tagged with the flag epitope and expressed in Ba/F3 cells expressing NF-κB-GFP. These cells were stimulated with a TLR7 ligand loxoribine. As a positive control, a TLR2 ligand Pam 3 CSK 4 was used because Ba/F3 cells endogenously express TLR2 and TLR1. TLR2-dependent GFP induction was seen in all the transfectants (Fig. 5A) . TLR7 ligand loxoribine failed to induce GFP in all the transfectants at 0.1 mM, as reported previously (18), or at 0.25 mM (Fig. 5A) . GFP induction was, however, weakly but significantly detected in Ba/F3 cells expressing wild type (WT) or C445S TLR7 mutant when the loxoribine concentration was increased up to 1 mM (Fig. 5A) . All the TLR7 mutants were subjected to immunoprecipitation and immunoprobing with anti-Flag (Fig. 5B) . Under reduced condition, only the C445S mutant was proteolytically cleaved, whereas the rest of the TLR7 mutants were not cleaved at all (Fig. 5B) . Under non-reduced conditions C98S mutant and a part of C475S and C722S mutants migrated faster than WT or C445S TLR7 (Fig. 5B) .
The effect of the epitope tag on TLR7 responses
The weak GFP induction by TLR7-Flag made functional analyses very difficult. We tried to enhance TLR7 responses. Although D34A Unc93B1 expression enhances TLR7 responses (18) , enhanced TLR7 responses may be distinct from physiological TLR7 responses. The flag epitope at the C-terminus might have hindered a downstream signaling pathway. Epitope tag-free TLR7 and its mutants were, therefore, expressed in Ba/F3 cells, and NF-κB-dependent GFP induction by TLR7 ligands was studied. Interestingly, much higher GFP induction was observed in WT and C445S TLR7 than flag-tagged TLR7 (Fig. 6A) . In contrast to the flag-tagged C722S TLR7 mutant, tag-free C722S TLR7 was able to induce GFP as much as WT or C445S TLR7. On the other hand, no GFP induction was seen in Ba/F3 cells expressing C98S or C475S TLR7.
These results were further confirmed by using a human kidney cell line HEK293T. HEK293T cells were transfected with constructs encoding TLR7 mutants and an NF-κB-luciferase reporter plasmid. These cells were stimulated with TLR7 ligand loxoribine or gardiquimod, and luciferase induction was determined. Expression of epitope tag-free TLR7 and luciferase was confirmed by flow cytometry staining with TLR7N mAb (Fig. 6B) and NF-κB activation by TNFα (Fig. 6C, open bars) , respectively. The results were similar to those using Ba/F3 cells in that C98S and C475S TLR7 failed to respond to TLR7 ligands (Fig. 6C) .
Biochemical analyses were next conducted with the Ba/ F3 transfectants used for GFP induction in Fig. 6(A) . Tag-free TLR7 expressed in Ba/F3 cells was immunoprecipitated with TLR7N mAb and immunoprobed with TLR7N or TLR7C pAb. Under reduced condition, TLR7N and TLR7C were detected in WT, C445S and C722S TLR7 but not in C98S or C475S TLR7 (Fig. 7A and B) . C98S and C475S mutations made TLR7 resistant to proteolysis. In the C445S TLR7 mutant, an additional signal was detected between TLR7F and TLR7C by anti-TLR7C pAb. C445S mutation may generate an additional proteocleavage site. Under non-reduced conditions only TLR7F was detected but TLR7N was not detected (Fig. 7C ). C98S and C475S TLR7 mutants migrated faster or slower, respectively, than WT TLR7 (Fig. 7C) , whereas C445S and C722S TLR7 mutants did not show any alteration in migration. Given that all the mutants showed similar TLR7F migration under reduced SDS-PAGE, mutations at C98 or C475 seemed to alter an intramolecular disulfide bond of TLR7. These results suggest that C98 and C775 are used for a disulfide bond linking TLR7N and TLR7C (see Discussion).
Cys98 and Cys475 are not required for the subcellular distribution of TLR7
Proteolytic cleavage was not observed in C98S or C475S TLR7. These TLR7 mutants may be altered in either TLR7 trafficking from ER to endosomes or in proteolytic cleavage by proteases. To address these possibilities, the subcellular distribution of the TLR7 mutants was determined by confocal imaging. TLR7 and calnexin, a marker for ER, were stained. WT, C445S and C722S TLR7s expressed in Ba/F3 cells were 418 TLR7-unique cysteines mostly detected around the nucleus and showed partial colocalization with ER (Fig. 8) . Considering that TLR7 is cleaved outside ER, partial localization of TLR7 outside ER suggests that TLR7 is partially cleaved in Ba/F3 cells. Consistent with this, TLR7F, TLR7N and TLR7C were all detected in WT, C445S and C722S TLR7s (Fig. 7A and B, lanes 3, 5 and 6 ). Although C98S and C475S TLR7 mutants were not cleaved, these mutants were detected outside ER as well as in ER (Fig. 8) , demonstrating that C98S and C475S mutations do not inhibit TLR7 trafficking from ER to endolysosomes.
Mutations in the cleavage site impair TLR7 responses
Given that C98S and C475S mutants normally exited ER, these mutations are likely to make TLR7 resistant to proteolytic cleavage. It remains to be clarified whether hyporesponsiveness of 
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C98S and C475S mutants is due to impairment of proteolytic cleavage of TLR7. To address this issue further, additional TLR7 mutants lacking the cleavage site or the N-terminal fragment were designed (Fig. 9A) . TLR7 mutants lacking 5, 6 or 8 amino acids including the cleavage site were expressed in Ba/F3 cells, immunoprecipitated with TLR7 mAb and immunoprobed with TLR7N pAb. TLR7N was very weakly but significantly detected in TLR7Δ5 but not in TLR7Δ6 or TLR7Δ8 mutants (Fig. 9B) , demonstrating that proteolytic cleavage of TLR7 was impaired by TLR7Δ5 mutation and completely abolished by TLR7Δ6 or TLR7Δ8 mutation. Functional analyses of these TLR7 mutants were next conducted. For functional analyses, we also studied TLR7 lacking TLR7N (TLR7C alone) to examine the requirement for TLR7N in TLR7 responses (Fig. 9A) . TLR7 mutants including TLR7C were expressed in HEK293 cells and ligand-dependent NF-kB activation was studied. TLR7Δ5 showed weak but significant NF-κB activation, whereas no NF-κB activation was seen in TLR7Δ6 or TLR7Δ8mutants. These results demonstrate that proteolytic cleavage of TLR7 positively correlates with TLR7 responses. TLR7C alone did not respond to TLR7 ligands (Fig. 9C) , suggesting a requirement for TLR7N in TLR7 responses.
Discussion
This study has determined that TLR7C starts at 461E or 462A and indicated the proteolytic cleavage sites of the TLR7 ectodomain between 460L and 461E or 461E and 462A. Resultant TLR7N was not cleaved off but linked by a disulfide bond with TLR7C. Endogenous TLR7 in BM-cDCs was processed but cleaved TLR7N remained in endolysosomes by being covalently linked with TLR7C. Taking into consideration that TLR9N is not linked to TLR9C by a disulfide bond, TLR7-unique cysteines were suggested to link TLR7N and TLR7C. Among the TLR7-unique cysteines, C98 in TLR7N and C475 in TLR7C were required for TLR7 responses. We expected that C98S or C475S mutation would make cleaved TLR7 fragments (TLR7C and TLR7N) detectable under non-reduced conditions. C98S and C475S TLR7 mutants were, however, not cleaved. Given that these TLR7 mutants were found outside ER, it is likely that these mutations make TLR7 resistant to proteolysis, instead of impairing TLR7 trafficking from ER. Such a drastic effect on TLR7 is probably due to conformation change by C98S or C475S mutation. The C98S TLR7 mutant migrated faster than WT TLR7 in non-reduced SDS-PAGE. On the other hand, C475S TLR7 largely migrated slower than WT TLR7. Under reduced conditions C98S and C475S mutants did not show any altered migration in SDS-PAGE. These differences in non-reduced SDS-PAGE are likely to be due to alteration in intramolecular disulfide bonds in C98S or C475S mutants. Fast-and slow-migrating TLR7 mutants would reflect acquisition or loss of an intramolecular disulfide bond, respectively. The loss of a disulfide bond by C475S mutation directly indicates that C475 is used for the intramolecular disulfide bond. C98 is likely to be linked with C475, but C98S mutation generated an additional disulfide bond instead of losing a disulfide bond. Conformation change due to the C98S mutation would make other cysteines including C475 closer to each other. Considering that the other two mutations at C445 or C722 did not alter TLR7 migration in non-reduced SDS-PAGE, C98 in TLR7N and C475 in TLR7C are likely to be employed for a disulfide bond between TLR7N and TLR7C.
Mutations at C98 or C475 made TLR7 resistant to proteolytic cleavage and abolished TLR7 responses. Moreover, mutations at the cleavage site made TLR7 resistant to proteolysis and abolished TLR7 responses, demonstrating positive correlation between proteolytic cleavage and TLR7 responses. These results suggest an indispensable role for proteolytic cleavage of the TLR7 ectodomain in TLR7 responses. TLR7N is covalently linked with truncated TLR7C, and therefore proteocleavage does not cleave TLR7N off from truncated TLR7C. Only TLR7C failed to respond to TLR7 ligands, suggesting that RNA is sensed by TLR7N + TLR7C. In relation to this, TLR3 is cleaved but the N-terminal fragment is shown to remain associated with truncated TLR3 (26) . TLR3 containing both TLR3N and TLR3C is suggested to primarily signal double-strand RNA. Further study needs to reveal roles for proteolytic cleavage and cleaved TLR7N in TLR7-dependent RNA sensing.
Proteolytic cleavage of endogenous TLR7 varied with cell lines. Endogenous TLR7 was partially cleaved in a macrophage cell line RAW264, but was completely cleaved in BM-cDCs. TLR7 proteolytic cleavage depends on expression of proteases and the subcellular distribution of TLR7. Proteases including cathepsins and asparagine endopeptidase or of the molecules regulating TLR7 trafficking such as Unc93B1, AP-3 (27, 28) or PRAT4A are likely to determine the degree of TLR7 cleavage.
The flag epitope at the C-terminus of TLR7 abolished TLR7 responses and proteolytic cleavage of C722S TLR7 mutant, demonstrating that the epitope tag at the C-terminus strongly affects TLR7 function. The flag epitope at the C-terminus is likely to directly hinder TLR7 signaling. Proteolytic cleavage and response of C722S TLR7 mutant were profoundly impaired by the flag epitope. Given the mutant-specific effect of the flag epitope on TLR7, we need to be careful about the results using epitope-tagged TLR7. Considering that all the previous reports studied epitope-tagged TLR7, further study needs to focus on endogenous TLR7 instead of epitopetagged TLR7. The newly established TLR7 mAb is a valuable tool for studying TLR7. 
TLR7-unique cysteines 421
Downloaded from https://academic.oup.com/intimm/article-abstract/25/7/413/732624 by guest on 10 January 2019
